Evidence map›Paper›PMID 42593640›Full record

ReviewInfection2026

Chagas disease: the peculiar relationship between parasite and host.

Marie-Andrea Atsé, Alicia Gómez-Barrio, Cristina Fonseca-Berzal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marie-Andrea AtséDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Pza. Ramón y Cajal s/n, Madrid, 28040, Spain.
Alicia Gómez-BarrioDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Pza. Ramón y Cajal s/n, Madrid, 28040, Spain.ORCID http://orcid.org/0000-0002-0347-758X
Cristina Fonseca-BerzalDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Pza. Ramón y Cajal s/n, Madrid, 28040, Spain. crfonseca@pdi.ucm.es.ORCID http://orcid.org/0000-0002-3031-900X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical course of Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, usually progresses from an acute to an indeterminate phase, both characterized by the lack of specific symptoms. Only one third of patients develop life-threatening manifestations associated with the chronic infection. This fact draws attention of the scientific community to understanding the role of the immune response in the course of the disease, which is the aim of this review. On the one hand, both innate and adaptive immune cells exert antiparasitic effects by respectively releasing nitric oxide and antibodies, as well as activating perforin/granzyme or Fas/FasL pathways. Moreover, nature of secreted cytokines (i.e., pro- or anti-inflammatory) polarizes the response towards Th1 or Th2: according to the phase of CD, these profiles can be detrimental or beneficial to the host. On the other hand, the parasite has developed strategies to escape from the immune system and successfully establish the chronic disease. Also, parasite persistence, together with the immunopathology generated by the infection, seems to be important for the onset of such symptomatic phase. Since the immune response evolves through CD progression and has close relationship with the severity of the disease, study of immune mediators deserves special attention, to identify intervention points for preventing CD evolution and developing more effective therapies.

Indexed as

Adaptive immunityImmune evasionImmunopathologyInnate immunityTrypanosoma cruzi

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.